GlassScriptPhysician profile
Elizabeth Granieri
NPI 1780975102
$14,098.59
in general payments reported to CMS, 2019-2025
55 companies · $3,201 in 2025
The $3,201 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,455 · 2020: $814 · 2021: $519 · 2022: $1,821 · 2023: $2,875 · 2024: $2,416 · 2025: $3,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,417 · Education: $73.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,417.36 |
| Education | $73.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,135.57 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Lilly USA, LLC | $1,710.41 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Amgen INC. | $1,090.87 | 2019-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $885.99 | 2019-2025 | Jardiance, Synjardy |
| Insulet Corporation | $627.30 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $597.08 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $585.46 | 2020-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $528.57 | 2021-2024 | |
| Abbvie INC. | $472.18 | 2019-2025 | |
| Boston Scientific Corporation | $466.53 | 2023-2024 | |
| Medtronic, INC. | $433.23 | 2022-2025 | Minimed 780g, Interstim |
| Sanofi-Aventis U.S. LLC | $411.96 | 2019-2025 | |
| Sequel Med Tech, LLC | $389.72 | 2024-2025 | Twiist |
| Abbott Laboratories | $369.08 | 2023-2025 | Freestyle Libre, Eterna, Freestyle Libre 3 |
| Medtronic Minimed, INC. | $277.55 | 2019-2020 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.94 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $217.36 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $208.41 | 2021-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $193.68 | 2022-2025 | Yorvipath, Skytrofa |
| Ascensia Diabetes Care US INC. | $189.44 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.22 | 2019-2020 | |
| Beta Bionics, INC. | $133.86 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $123.62 | 2024-2025 | Cequr Simplicity |
| Dexcom, INC. | $122.50 | 2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $121.57 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $104.27 | 2019-2022 | |
| Kyowa Kirin, INC. | $97.20 | 2025 | |
| Mannkind Corporation | $91.87 | 2019-2024 | |
| Antares Pharma, INC. | $84.78 | 2024-2025 | Xyosted |
| Tandem Diabetes Care, INC. | $79.80 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $73.90 | 2023-2025 | Qutenza |
| Amphastar Pharmaceuticals, INC. | $69.11 | 2024-2025 | |
| Chiesi USA, INC. | $63.15 | 2025 | Mycapssa, Myalept |
| Pfizer INC. | $61.94 | 2019-2025 | |
| Soleno Therapeutics, INC. | $55.31 | 2025 | Vykat Xr |
| Azurity Pharmaceuticals, INC. | $50.00 | 2022-2023 | Triptodur |
| Ibsa Pharma INC. | $49.97 | 2020-2023 | Tirosint, Licart |
| Ultragenyx Pharmaceutical INC. | $48.87 | 2019-2021 | |
| Radius Health, INC. | $48.13 | 2023-2025 | Tymlos |
| Neurocrine Biosciences, INC. | $47.16 | 2025 | |
| Novartis Pharmaceuticals Corporation | $42.77 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $38.74 | 2019 | |
| Amneal Pharmaceuticals LLC | $36.01 | 2023-2024 | Unithroid |
| Amryt Pharma Holdings LTD | $35.61 | 2022-2023 | Mycapssa |
| Recordati_rare_diseases_inc. | $31.03 | 2022-2023 | Signifor Lar, Isturisa |
| Verity Pharmaceuticals INC. | $28.66 | 2025 | Tlando |
| Janssen Pharmaceuticals, INC | $27.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.64 | 2020 | |
| Almatica Pharma LLC | $21.53 | 2025 | Teriparatide |
| Endo Pharmaceuticals INC. | $17.19 | 2019 | |
| Endo USA, INC. | $16.75 | 2025 | Supprelin |
| Eusa Pharma (US) LLC | $16.51 | 2022 | |
| Esteve Pharmaceuticals LLC | $15.67 | 2025 | Metopirone |
| Grt US Holding, INC. | $15.15 | 2022 | |
| Shire North American Group INC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Granieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.